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Lupus Nephropathy S49Figure 2. Renal survival rates of LN patients with class IV and IV+V (The 5-, 10-,
and 20-year renal survival rates of patients with class IV were 89.1%, 82.7% and
60.3%, respectively; with class IV+V, 90.8%, 82.7%, and 54.7%, respectively).Figure 3. Renal survival rates of LN patients with subclass IV-S and IV-G (The
5-, 10-, and 20-year renal survival rates of patients with subclass IV-S were
91.6%, 86.2% and 69.6%, respectively; with subclass IV-G, 88.4%, 81.9% and
58.9%, respectively).
Conclusion: LN patients with proliferative lesions combined with membra-
nous lesions presented with both clinicopathological characteristics of the
two types of lesions, but their renal outcomes were not different from pa-
tients with pure proliferative lesions. Patients with subclass IV-S and subclass
IV-G LN had their own clinicopathological characteristics respectively, but the
division of class IV into the two subclasses was not meaningful for predicting
renal outcomes. In addition to glomerular lesions, tubulointerstitial and
vascular lesions were also predictors for poor renal outcomes.http://dx.doi.org/10.1016/j.hkjn.2015.08.1310068
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Objective: To observe and analyze the clinical manifestations and prognosis
of systemic lupus erythematosus (SLE) complicated with intestinal pseudo-
obstruction (IPO).
Methods: From January 2004 to April 2014, 30 patients with SLE and IPO
were enrolled to analysis the clinical manifestations, laboratory tests, imag-
ing characteristics, treatment and prognosis.
Results: They were 26 females and 4 males, with mean age 26.1  11.2
years old. The median history of SLE was 27.5 months. The SLE-DAI score
was 11.2  7.4 when IPO occurred. 6 patients had identified induction fac-
tors (5 cases had unclean food, 1 case had respiratory tract infection). The
most common manifestions of IPO were nausea and vomiting (76.6%),
abdominal pain (66.7%), diarrhea (56.7%), bloating (30%). More than 75%
patients showed intestinal obstruction in KUB and abdominal CT. 7 patients
with hydronephrosis and h^ydroureters concomitantly. Most cases had ane-
mia (96.7%). 6 patients had thrombocytopenia and 8 patients had leuko-
penia. The direct Coomb’s tests were positive in 4 cases. All patients had
hypocomplementemia, with positive autoantidodies of ds_DNA (51.7%),
anticardiolipin antibody (30.4%), lupus anticoagulant (43.8%) and anti-
C1q antibody (47.4%). 29 patients were treated with aggressive immuno-
suppressive therapy, 10 patients received methylprednisolone plus
(0.75e3.00 g), 11 patients received gamma immunoglobulin therapy
(15e100 g). 29 patients were improved after therapy. The median remis-
sion time of IPO was 12 days (8e19 days). There were 24 patients fol-
lowed-up for 1e60 months; 2 died of complications, 5 patients had
relapse of IPO, 4 cases entered ESRD. Patients had stable condition of
lupus.
Conclusion: SLE complicated with IPO is relatively rare in clinical. The mani-
festation is diversity and easily missed diagnose or misdiagnosis. Early diag-
nosis and timely immunosuppressive therapy could improve the prognosis.http://dx.doi.org/10.1016/j.hkjn.2015.08.132
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Objective: The dosages of mycophenolate mofetil (MMF) used for the
treatment of lupus nephritis (LN) are based on experience in renal trans-
plant recipients. The role of therapeutic drug monitoring of mycophenolic
acid (MPA) level in managing LN remains unclear. This study aimed to inves-
tigate the relationship between MPA levels and clinical parameters in LN
patients.
Methods: We prospectively recruited LN patients who received maintenance
treatment with prednisolone and MMF during disease remission. Blood MPA
level at 1, 2, 4, 8, 10 and 12 hours (i.e. C1, C2, C4, C8, C10 and C12) after
MMF administration was measured with an enzymatic assay upon recruit-
ment and repeated at 6-month intervals for 24 months, and at occurrence
of clinically significant events. The MPA pharmacokinetics and its clinical
correlations were assessed.
Results: 51 patients were studied (mean prednisolone and MMF dosages
were 6.2  1.8 mg/d and 1284  493 mg/d respectively at baseline). C1,
C2 and C12 MPA levels were 9.9  8.7 mg/L, 8.6  6.2 mg/L,
1.9  1.4 mg/L during disease quiescence. C1, C2 and C12 MPA levels showed
a positive relationship with AUC0-12 (r Z 0.52, 0.85 and 0.77; p Z 0.004,
<0.001 and <0.001 respectively). C12 correlated negatively with hemoglo-
bin, white cell and platelet counts (r Z 0.359, 0.226, 0.20;
p Z 0.001, 0.010 and 0.024 respectively). No association exist between
C12 and anti-dsDNA, serum creatinine or 24-hour urine protein excretion
(pZ 0.53, 0.07 and 0.37 respectively). C1 and C2 did not show any relation-
ship with clinical or serological parameters. Clinically significant events
included infection in 2 patients, gastrointestinal disturbances in 3 patients,
